Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
Tenaya Therapeutics (NASDAQ: TNYA), a clinical-stage biotechnology company focused on developing curative therapies for heart disease, has announced its participation in two major investor conferences in March 2025.
The company will be featured at:
- TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, with a company presentation from 1:10 PM ET to 1:40 PM ET
- Leerink Partners Global Healthcare Conference 2025 on Wednesday, March 12, participating in a fireside chat from 8:40 AM ET to 9:10 AM ET
CEO Faraz Ali will represent the company at both events. Live and archived webcasts will be available through Tenaya's website Investors section, with replays accessible for approximately 30 days after each conference.
Tenaya Therapeutics (NASDAQ: TNYA), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di terapie curative per le malattie cardiache, ha annunciato la sua partecipazione a due importanti conferenze per investitori a marzo 2025.
L'azienda sarà presente a:
- TD Cowen's 45th Annual Health Care Conference martedì 4 marzo, con una presentazione aziendale dalle 13:10 ET alle 13:40 ET
- Leerink Partners Global Healthcare Conference 2025 mercoledì 12 marzo, partecipando a una chiacchierata informale dalle 8:40 ET alle 9:10 ET
Il CEO Faraz Ali rappresenterà l'azienda in entrambi gli eventi. Le dirette e le registrazioni delle webcasts saranno disponibili attraverso la sezione Investitori del sito web di Tenaya, con le riproduzioni accessibili per circa 30 giorni dopo ogni conferenza.
Tenaya Therapeutics (NASDAQ: TNYA), una empresa de biotecnología en etapa clínica centrada en desarrollar terapias curativas para enfermedades cardíacas, ha anunciado su participación en dos importantes conferencias para inversores en marzo de 2025.
La empresa estará presente en:
- TD Cowen's 45th Annual Health Care Conference el martes 4 de marzo, con una presentación de la empresa de 1:10 PM ET a 1:40 PM ET
- Leerink Partners Global Healthcare Conference 2025 el miércoles 12 de marzo, participando en una charla informal de 8:40 AM ET a 9:10 AM ET
El CEO Faraz Ali representará a la empresa en ambos eventos. Las transmisiones web en vivo y grabadas estarán disponibles a través de la sección de Inversores del sitio web de Tenaya, con repeticiones accesibles durante aproximadamente 30 días después de cada conferencia.
테나야 테라퓨틱스 (NASDAQ: TNYA)는 심장병에 대한 치유 치료법 개발에 집중하는 임상 단계의 생명공학 회사로, 2025년 3월에 열리는 두 개의 주요 투자자 회의에 참여한다고 발표했습니다.
회사는 다음 회의에 참석할 예정입니다:
- TD Cowen 제45회 연례 의료 회의가 3월 4일 화요일에 열리며, 회사 발표는 오후 1시 10분 ET부터 1시 40분 ET까지 진행됩니다.
- Leerink Partners 글로벌 의료 회의 2025가 3월 12일 수요일에 열리며, 오전 8시 40분 ET부터 9시 10분 ET까지 비공식 대화에 참여합니다.
CEO 파라즈 알리는 두 행사 모두에서 회사를 대표할 것입니다. 생중계 및 아카이브된 웹캐스트는 테나야의 웹사이트 투자자 섹션을 통해 제공되며, 각 회의 후 약 30일 동안 재생이 가능합니다.
Tenaya Therapeutics (NASDAQ: TNYA), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies curatives pour les maladies cardiaques, a annoncé sa participation à deux grandes conférences pour investisseurs en mars 2025.
L'entreprise sera présente à :
- TD Cowen's 45th Annual Health Care Conference le mardi 4 mars, avec une présentation de l'entreprise de 13h10 ET à 13h40 ET
- Leerink Partners Global Healthcare Conference 2025 le mercredi 12 mars, participant à une discussion informelle de 8h40 ET à 9h10 ET
Le PDG Faraz Ali représentera l'entreprise lors des deux événements. Des webcasts en direct et archivés seront disponibles via la section Investisseurs du site Web de Tenaya, avec des rediffusions accessibles pendant environ 30 jours après chaque conférence.
Tenaya Therapeutics (NASDAQ: TNYA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung heilender Therapien für Herzkrankheiten konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im März 2025 bekannt gegeben.
Das Unternehmen wird auf folgenden Veranstaltungen vertreten sein:
- TD Cowen's 45th Annual Health Care Conference am Dienstag, den 4. März, mit einer Unternehmenspräsentation von 13:10 Uhr ET bis 13:40 Uhr ET
- Leerink Partners Global Healthcare Conference 2025 am Mittwoch, den 12. März, mit einer Teilnahme an einem informellen Gespräch von 8:40 Uhr ET bis 9:10 Uhr ET
CEO Faraz Ali wird das Unternehmen bei beiden Veranstaltungen vertreten. Live- und aufgezeichnete Webcasts werden über den Investorenbereich der Website von Tenaya verfügbar sein, mit Wiederholungen, die etwa 30 Tage nach jeder Konferenz zugänglich sind.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in TD Cowen’s 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025. Details are as follows:
TD Cowen 45th Annual Health Care Conference
Date: Tuesday, March 4
Time: 1:10 PM ET – 1:40 PM ET
Format: Company Presentation
Leerink Partners Global Healthcare Conference 2025
Date: Wednesday, March 12
Time: 8:40 AM ET – 9:10 AM ET
Format: Fireside Chat
The live and archived webcast of the presentation and fireside chat may be accessed from the Investors section of Tenaya’s website. A replay of the webcasts will be available on the Tenaya website for approximately 30 days following each conference.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya’s pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit www.tenayatherapeutics.com.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
FAQ
When is Tenaya Therapeutics (TNYA) presenting at the TD Cowen Healthcare Conference 2025?
What time is TNYA's fireside chat at the Leerink Partners Conference 2025?
How long will TNYA's conference webcasts be available for replay?
Where can investors access TNYA's March 2025 conference presentations?
